About Us

---

Infinitely varied in its effects on the human body, cancer has confounded the medical profession for 3,000 years. The most dreaded of dreaded diseases continues to cause incalculable human suffering around the world. 

There is anguish and anxiety in patients forced to choose between the lesser of two evils—one of over 200 varieties of the disease itself, or the devastating treatment of the disease. Cancer therapy has been likened to beating a dog with a club in an attempt to rid the animal of fleas. 

The American Cancer Society recently published sobering statistics: 2023 Cancer Facts & Figures. This report from Cancer.org states that 1.958 million new cancer cases in the United States are expected to be diagnosed, and 609,820 cancer patients are projected to die this year. 

The war against cancer is growing increasingly impatient. The clock is ticking for cancer patients and their families; they simply cannot hurry up and wait any longer. There is a real sense of urgency. The need for breakthroughs in the laboratory and new therapies in the clinic is overwhelming. 

As the famous cancer researcher, Doctor Sidney Farber, once uttered in exasperation: “The patients with cancer who are going to die this year cannot wait; nor is it necessary, in order to make great progress in the cure of cancer, for us to have the full solution of all the problems of basic research. The history of medicine is replete with examples of cures obtained years, decades, and even centuries before the mechanisms of action was understood for these cures.”

It has been my experience that in working to simplify the complexity of any problem, it is highly useful to reason backwards. This time-honored scientific method of backward chaining in evolutionary biology calls for identifying the first phenomena in a timeline. 

The origin of the biological connection between plants and megafauna can be traced back to the growth of autotrophic green algae some 3.5 billion years ago. According to the endosymbiotic theory, algae evolved into nucleus-bearing organisms: the primeval ancestors of humans. 

The physical synergy and cognitive symbiosis between plant and animal kingdoms is a burgeoning field at the frontiers of medical science. This space in biology is where the action is relevant to offering clues to cancer, and it may ultimately yield treatments for cancer.

I have constructed, deconstructed, and reconstructed my hypothesis using step-by-step scaffolding strategies to analyze the biological properties of Allelopathy, and then connect Horizontal Gene Transfer as the pathway cancer researchers may tread to discover targeted therapies. 

Allelopathy in the natural world is a unique biological phenomenon. It's a instinctive process that takes place when plants produce selective allelochemicals that inhibit or influence the growth and survival of other organisms. 

Horizontal Gene Transfer occurs when genetic materials or DNA is moved or transferred from one multicellular organism to another. This gene jumping is happening outside the lines of the normal transmission of DNA: parents passing genes to their biological children. 

In the final analysis, I believe scientists may discover that Allelopathy and Horizontal Gene Transfer are conjoined in the biology of preventing and treating cancer. A robust scientific inquiry may usher in the advent of a whole new era in medicine. 

Why would an 18-year old undergraduate student at Princeton University majoring in molecular biology be so presumptuous to postulate a theory about stopping cancer? 

From the age of six, I have been acutely aware of cancer, watching my dad—who doubles as my hero—battle twice-relapsed Acute Myeloid Leukemia (AML) at the Mayo Clinic in Rochester, Minnesota. It is no coincidence; this disease is profoundly personal to me. 

I have spent years methodically studying Allelopathy and Horizontal Gene Transfer. I have attempted to connect-the-dots in the interest of protecting and preserving my dad’s continued existence, in the hopes he would have More Life. This work has been a labor of love. 

At the heart of my efforts, is a relentless dedication to become a doctor. I have a burning desire to make a difference in the lives of patients and their families. I have pushed myself further, pushed myself harder than I ever dreamed possible. 

This motivation compelled me to start More Life Genomics—the first and only Allelopathy via Horizontal Gene Transfer discovery platform—and file a provisional patent application for ANKH-22, our lead development candidate. 

There are a number of essential questions that still must be answered. The exact scientific process and molecular mechanism of action involved in the disruptive methodology of my hypothesis remain a mystery. More investigation needs to be done. 

I would like to invite you to join me in this collaborative effort to transform science into medicines. The expanse of medicine depends on the breadth of our imagination. 

Alexis Korzan, Founder